MedTrace Logo

Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease

NCT06212089 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-06-06

No results posted yet for this study

Summary

The purpose of this study to evaluate the safety and pharmacokinetics of TR-012001 in patients with Parkinson's disease when TR-012001 or placebo is administered.

Conditions

  • Parkinson Disease

Interventions

DRUG

TR-012001

A single dose of TR-012001 will be administered.

OTHER

Placebo

A single dose of placebo will be administered.

Sponsors & Collaborators

  • SNLD, Ltd.

    lead INDUSTRY

Principal Investigators

  • Akihisa Mori, PhD · SNLD, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-28
Primary Completion
2024-04-26
Completion
2024-05-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212089 on ClinicalTrials.gov